Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy

Sheng, Li; Zhu, Liangjun; Yao, Li; Xia, Lei; Pan, Lei

doi:10.1186/1471-230x-14-154

Cited by 11 publications

(8 citation statements)

References 27 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study in line with other authors [9], has not confirmed that overexpression of TYMS protein or transcript predicts poor outcome in colorectal cancer patients [7,8]. Similarly, the results of studies indicating potential prognostic role of DPYD [10,11] or TYMP [12] expression for survival of colorectal cancer patients after 5-FU-treatment were not replicated.…”

Section: Discussionsupporting

confidence: 58%

See 1 more Smart Citation

267 Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma

Kunická¹,

Procházka²,

Krus³

et al. 2015

European Journal of Cancer

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 58%

“…Recent studies have shown that overexpression of TYMS transcript predicts poor outcome in colorectal cancer patients [7,8]. However, another contemporary study has not confirmed these observations as intratumoral TYMS transcript level was not predictive in patients with colorectal cancer of stage II and III [9].…”

Section: Introductionmentioning

confidence: 99%

267 Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma

Kunická¹,

Procházka²,

Krus³

et al. 2015

European Journal of Cancer

View full text Add to dashboard Cite

“…They determined that the mRNA expression level of ERCC1 was not significantly associated with the DFS in Chinese patients with stage II to III colorectal cancer who received 5-FU and oxaliplatin-based adjuvant chemotherapy; neither did they find a significant association between DFS and thymidylate synthase. On the other hand, another study of patients with stage III colon cancer who received oxaliplatin-based adjuvant chemotherapy reported that the 5-year DFS was significantly higher in patients with ERCC1-negative tumors (72%) than in patients with ERCC1-positive tumors (54%) (hazard ratio, 1.98; 95% confidence interval, 1.19-3.31; P = 0.009) [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting

Kim

Seo

et al. 2015

Ann Coloproctol

View full text Add to dashboard Cite

PurposeThe purpose of this study was to identify the excision repair cross-complementation group 1 (ERCC1) as a predictive marker for FOLFOX adjuvant chemotherapy in stages II and III colon cancer patients.MethodsA total of 166 high risk stages II and III colon cancer patients were retrospectively enrolled in this study, and data were collected prospectively. They underwent a curative resection followed by FOLFOX4 adjuvant chemotherapy. We analyzed ERCC1 expression in the primary colon tumor by using immunohistochemical staining. The oncological outcomes included the 5-year disease-free survival (DFS) rate. The DFS was analyzed by using the Kaplan-Meier method with the log-rank test. A Cox proportional hazard model was used for the prognostic analysis.ResultsERCC1-positive expression was statistically significant in the older patients (P = 0.032). In the multivariate analysis, the prognostic factors for DFS were female sex (P = 0.016), N stage (P = 0.009), and postoperative carcinoembryonic antigen level (P = 0.001), but ERCC1 expression was not a statistically significant prognostic factor for DFS in the univariate analysis (P = 0.397). The 5-year DFS rate was not significantly associated with the ERCC1 expression in all patients (P = 0.396) or with stage III disease (P = 0.582).ConclusionWe found that ERCC1 expression was not significantly correlated with the 5-year DFS as reflected by the oncologic outcomes in patients with high-risk stages II and III colon cancer treated with FOLFOX adjuvant chemotherapy.

show abstract

“…5-Fluorouracil (5-FU) is a cell cycle specific drug that can inhibit thymidylate synthase activity in tumor cells in vivo by blocking the biosynthesis of deoxythymidine from deoxyuridine and eventually inhibiting DNA synthesis [1,2]. Furthermore, it also can prevent uracil and orotic acid uptake into RNA to inhibit the effects of RNA, and thus interferes with the biosynthesis of RNA, DNA, and proteins [3,4].…”

Section: Introductionmentioning

confidence: 99%

Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo

Cheng

Zhi

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Our previous study found that a nanoparticle drug delivery system that operates as a drug carrier and controlled release system not only improves the efficacy of the drugs but also reduces their side effects. However, this system could not efficiently target hepatoma cells. The aim of this study was to synthesize biotin-modified galactosylated chitosan nanoparticles (Bio-GC) and evaluate their characteristics in vitro and in vivo. Methods: Bio-GC nanomaterials were synthesized, and confirmed by fourier transform infrared spectroscopy (FT-IR) and hydrogen-¹ nuclear magnetic resonance (¹H-NMR). The liver position and cancer target property of Bio-GC nanoparticles in vitro and in vivo was tested by confocal laser and small animal imaging system. The characteristics of Bio-GC/5-fluorouracil (5-FU) nanoparticles in vitro and in vivo were explored by cell proliferation, migration and cytotoxicity test, or by animal experiment. Results: Bio-GC nanoparticles were synthesized with biodegradable chitosan as the nanomaterial skeleton with biotin and galactose grafts. Bio-GC was confirmed by FT-IR and ¹H-NMR. Bio-GC/5-FU nanoparticles were synthesized according to the optimal mass ratio for Bio-GC/5-FU (1: 4) and had a mean particle size of 81.1 nm, zeta potential of +39.2 mV, and drug loading capacity of 8.98%. Bio-GC/5-FU nanoparticles had sustained release properties (rapid, steady, and slow release phases). Bio-GC nanoparticles targeted liver and liver cancer cell in vitro and in vivo, and this was confirmed by confocal laser scanning and small animal imaging system. Compared with GC/5-FU nanoparticles, Bio-GC/5-FU nanoparticles showed more specific cytotoxic activity in a dose- and time-dependent manner and a more obvious inhibitory effect on the migration of liver cancer cells. In addition, Bio-GC/5-FU nanoparticles significantly prolonged the survival time of mice in orthotopic liver cancer transplantation model compared with other 5-FU nanoparticles or 5-FU alone. Bio-GC (0.64%) nanomaterial had no obvious cytotoxic effects on cells; thus, the concentration of Bio-GC/5-FU nanoparticles used was only 0.04% and showed no toxic effects on the cells. Conclusion: Bio-GC is a liver- and cancer-targeting nanomaterial. Bio-GC/5-FU nanoparticles as drug carriers have stronger inhibitory effects on the proliferation and migration of liver cancer cells compared with 5-FU in vitro and in vivo.

show abstract

Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy

Cited by 11 publications

References 27 publications

267 Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma

267 Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting

Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo

Contact Info

Product

Resources

About